chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually has chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable and treatable disease.

Chronic%20obstructive%20pulmonary%20disease Management

Monitoring

Prior to discharge from the hospital, check the patient based on the following criteria:

  • Able to use long-acting either beta2-agonists and/or anticholinergics with or without inhaled corticosteroids
  • Inhaled beta2-agonist is needed every 4 hours or less frequently
  • Able to walk across the room (if previously ambulatory)
  • Able to eat and sleep without frequent interruptions due to breathing difficulty
  • Clinically stable for 12-24 hours
  • ABG stable for 12-24 hours
  • Patient and caregiver adequately understand correct medication use
  • Home care arrangements (eg O2 delivery) are in place
  • Patient, family and physician are confident that patient can manage well

Follow Up

  • A follow-up assessment must be carried out within 4-12 weeks following discharge from hospital for exacerbations
  • Check patient’s ability to cope in his environment
  • Measure FEV1
  • Check inhaler technique
  • Check understanding and ability to follow treatment regimen
  • Assess need for long-term O2 therapy and/or home nebulizer for patients with very severe COPD
  • Check status of comorbidities
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.

Christina Lau, 23 Jun 2020

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.